Anti-NMDA receptor encephalitis explained

Anti-NMDA receptor encephalitis
Synonyms:NMDA receptor antibody encephalitis, anti-N-methyl-D-aspartate receptor encephalitis, anti-NMDAR encephalitis
Speciality:Neurology
Symptoms:Early: Fever, headache, feeling tired, psychosis, agitated
Later: Seizures, decreased breathing, blood pressure and heart rate variability
Complications:Long term mental or behavioral problems
Onset:Over days to weeks[1]
Risks:Ovarian teratoma, unknown
Diagnosis:Specific antibodies in the cerebrospinal fluid
Differential:Viral encephalitis, acute psychosis, neuroleptic malignant syndrome
Treatment:Immunosuppresive medication, surgery
Medication:Corticosteroids, intravenous immunoglobulin (IVIG), plasma exchange, azathioprine
Prognosis:Typically good (with treatment)
Frequency:Rare
Deaths:~4% risk of death

Anti-NMDA receptor encephalitis is a type of brain inflammation caused by antibodies.[2] Early symptoms may include fever, headache, and feeling tired. This is then typically followed by psychosis which presents with false beliefs (delusions) and seeing or hearing things that others do not see or hear (hallucinations). People are also often agitated or confused. Over time, seizures, decreased breathing, and blood pressure and heart rate variability typically occur. In some cases, patients may develop catatonia.[3]

About half of cases are associated with tumors, most commonly teratomas of the ovaries.[2] Another established trigger is herpesviral encephalitis, while the cause in other cases is unclear.[2] [4] The underlying mechanism is autoimmune, with the primary target being the GluN1 subunit of the N-methyl-D-aspartate receptors (NMDAR) in the brain.[5] Diagnosis is typically based on finding specific antibodies in the cerebrospinal fluid.[5] MRI of the brain is often normal. Misdiagnosis is common.

Treatment is typically with immunosuppresive medication and, if a tumor is present, surgery to remove it.[5] With treatment, about 80% of cases have a good outcome.[5] Outcomes are better if treatment is begun earlier.[6] Long-term mental or behavioral problems may remain.[6] About 4% of those affected die from the condition.[6] Recurrence occurs in about 10% of people.[5]

The estimated number of cases of the disease is one in 1.5 million people per year.[7] [4] The condition is relatively common compared to other paraneoplastic disorders.[6] About 80% of those affected are female.[6] It typically occurs in adults younger than 45 years old, but it can occur at any age.[2] [8] The disease was first described by Josep Dalmau in 2007.[5] [9]

Signs and symptoms

Prior to the development of a symptom complex that is specific to anti-NMDA receptor encephalitis, people may experience prodromal symptoms, including headaches, flu-like illness, or symptoms similar to an upper respiratory infection. These symptoms may be present for weeks or months prior to disease onset.[10] Beyond the prodromal symptoms, the disease progresses at varying rates, and patients may present with a variety of neurological symptoms. During the initial stage of the disease, symptoms vary slightly between children and adults. However, behavior changes are a common first symptom within both groups. These changes often include agitation, paranoia, delusions,[11] psychosis, and violent behaviors.[12] Other common manifestations include seizures and bizarre movements, mostly of the lips and mouth, but also including pedaling motions with the legs or hand movements resembling playing a piano . Some other symptoms typical during the disease onset include impaired cognition, memory deficits, and speech problems (including aphasia, perseveration or mutism).[13]

The symptoms usually appear psychiatric in nature, which may confound the differential diagnosis. In many cases, this leads to the illness going undiagnosed.[14] As the disease progresses, the symptoms become medically urgent and often include autonomic dysfunction, hypoventilation, cerebellar ataxia, loss of feeling on one side of the body,[15] loss of consciousness, or catatonia.[16] During this acute phase, most patients require treatment in an intensive care unit to stabilize breathing, heart rate, and blood pressure. One distinguishing characteristic of anti-NMDA receptor encephalitis is the concurrent presence of many of the above listed symptoms. The majority of patients experience at least four symptoms, with many experiencing six or seven over the course of the disease.[13]

Pathophysiology

The condition is mediated by autoantibodies that target NMDA receptors in the brain.[17] These can be produced by cross reactivity with NMDA receptors in teratomas, which contain many cell types, including brain cells, and thus present a window in which a breakdown in immunological tolerance can occur. Other autoimmune mechanisms are suspected for patients who do not have tumors. Whilst the exact pathophysiology of the disease is still debated, empirical evaluation of the origin of anti-NMDA receptor antibodies in serum and cerebrospinal fluid leads to the consideration of two possible mechanisms.

These mechanisms may be informed by some simple observations. Serum NMDA receptor antibodies are consistently found at higher concentrations than cerebrospinal fluid antibodies, on average ten times higher.[18] [19] This strongly suggests the antibody production is systemic rather than in the brain or cerebrospinal fluid. When concentrations are normalized for total IgG, intrathecal synthesis is detected. This implies that there are more NMDA receptor antibodies in the cerebrospinal fluid than would be predicted given the expected quantities of total IgG.

  1. Passive access involves the diffusion of antibodies from the blood across a pathologically disrupted blood-brain barrier (BBB).[20] This cellular filter, separating the central nervous system from the circulatory system, normally prevents larger molecules from entering the brain. A variety of reasons for such a collapse in integrity have been suggested, with the most likely answer being the effects of acute inflammation of the nervous system. Likewise, the involvement of corticotropin releasing hormone on mast cells in acute stress has been shown to facilitate BBB penetration.[21] However, it is also possible that the autonomic dysfunction manifested in many patients during the later phases of the condition aids antibody entry. For example, an increase in blood pressure would force larger proteins, such as antibodies, to extravasate into the cerebrospinal fluid.
  2. Intrathecal production (production of antibodies in the intrathecal space) is also a possible mechanism.[22] Dalmau et al. demonstrated that 53 out of 58 patients with the condition had at least partially preserved BBBs, whilst having a high concentration of antibodies in the cerebrospinal fluid. Furthermore, cyclophosphamide and rituximab, drugs used to eliminate dysfunctional immune cells, have been shown to be successful second-line treatments in patients where first-line immunotherapy has failed.[23] These destroy excess antibody-producing cells in the thecal sac, thus alleviating the symptoms.

A more sophisticated analysis of the processes involved in antibody presence in the cerebrospinal fluid hints at a combination of these two mechanisms in tandem.

Antibodies

Once the antibodies have entered the CSF, they bind to the NR1 subunit of the NMDA receptor. There are three possible methods in which neuronal damage occurs.

  1. A reduction in the density of NMDA receptors on the post synaptic knob, due to receptor internalization once the antibody has bound. This is dependent on antibodies cross linking.[24]
  2. The direct antagonism of the NMDA receptor by the antibody, similar to the action of the classic dissociative anesthetics phencyclidine and ketamine.
  3. The recruitment of the complement cascade via the classical pathway (antibody-antigen interaction). Membrane attack complex (MAC) is one of the end products of this cascade[25] and can insert into neurons as a molecular barrel, allowing water to enter. The cell subsequently lyses. Notably, this mechanism is unlikely as it causes the cell to die, which is inconsistent with current evidence.

Diagnosis

First and foremost is a high level of clinical suspicion, especially in young adults showing abnormal behavior as well as autonomic instability. Clinical examination may further reveal delusions and hallucinations, which can aid diagnostic efforts.

The initial investigation usually consists of clinical examination, MRI of the brain, an EEG, and a lumbar puncture for CSF analysis. MRI of the brain may show abnormalities in the temporal and frontal lobes, but do so in less than half of cases. A FDG-PET scan of the brain may show abnormalities in cases when the MRI scan is normal.[26] EEG is abnormal in almost 90% of cases and typically shows general or focal slow wave activity.[27] CSF analysis often shows inflammatory changes with increased levels of white blood cells, total protein and the presence of oligoclonal bands.[28] NMDA receptor antibodies can be detected in serum and/or CSF. Whole body FDG-PET is usually performed as a part of tumor screening. Gynecological ultrasound or a pelvic MRI might be performed to search for an ovarian teratoma in women.

Diagnostic criteria for probable and definite anti-NMDA receptor encephalitis have been proposed to facilitate diagnosis at an early stage of the disease and help initiate early treatment.[29]

Management

If a person is found to have a tumor, the long-term prognosis is generally better and the chance of relapse is much lower. This is because the tumor can be removed surgically, thus eradicating the source of autoantibodies. In general, early diagnosis and aggressive treatment is believed to improve patient outcomes, but this remains impossible to know without data from randomized controlled trials. Given that the majority of patients are initially seen by psychiatrists, it is critical that all physicians (especially psychiatrists) consider anti-NMDA receptor encephalitis as a possible cause of acute psychosis in young patients with no past neuropsychiatric history.

Prognosis

The recovery process from anti-NMDAR encephalitis can take many months. The symptoms may reappear in reverse order: The patient may begin to experience psychosis again, leading many people to falsely believe the patient is not recovering. As the recovery process continues on, the psychosis fades. Lastly, the person's social behavior and executive functions begin to improve.

Epidemiology

The estimated number of cases of the disease is 1.5 per million people per year.[4] According to the California Encephalitis Project, the disease has a higher incidence than its individual viral counterparts in patients younger than 30.[31] The largest case series as of 2013 characterized 577 people with anti-NMDA receptor encephalitis. The data were limited, but provides the best approximation of disease distribution. It found that women make up 81% of cases. Disease onset is skewed toward children, with a median age of diagnosis of 21 years. Over a third of cases were children, while only 5% of cases were patients over the age of 45. This same review found that 394 out of 501 patients (79%) had a good outcome by 24 months.[32] 30 people (6%) died, and the rest were left with mild to severe deficits. The study mentioned that of the 38% presenting with tumors, 94% of those presented with ovarian teratomas. Within that subset, African & Asian women were more likely to have a tumor, but this was not relevant to the prevalence of the disease within those racial groups.

Society and culture

Anti-NMDA receptor encephalitis is suspected of being an underlying cause of historical accounts of demonic possession.[33] [34] [35]

New York Post reporter Susannah Cahalan wrote a book titled Brain on Fire: My Month of Madness about her experience with the disease.[36] This has subsequently been turned into a film of the same name.[37]

Dallas Cowboys defensive lineman Amobi Okoye spent 17 months battling anti-NMDA receptor encephalitis. In addition to three months in a medically-induced coma, he experienced a 145-day memory gap and lost 78 pounds. He returned to practice on October 23, 2014.[38]

In the Japanese movie called The 8-Year Engagement, a young Japanese woman ends up being in a coma due to anti-NMDA receptor encephalitis.

Knut, a polar bear at the Berlin Zoological Garden that died on 19 March 2011, was diagnosed with anti-NMDA receptor encephalitis in August 2015. This was the first case discovered in a non-human animal.[39] [40] [41]

In Hannibal, Will Graham was affected by NMDA receptor or antibody encephalitis, also known as anti-NMDAR encephalitis.[42]

The TV series Something's Killing Me featured an episode called "Into Madness" that featured two cases of the disease.[43]

See also

External links

Notes and References

  1. Book: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE . Abeloff's Clinical Oncology E-Book . 2013 . Elsevier Health Sciences . 978-1-4557-2881-7 . 600 . en.
  2. Venkatesan A, Adatia K . Anti-NMDA-Receptor Encephalitis: From Bench to Clinic . ACS Chemical Neuroscience . 8 . 12 . 2586–2595 . December 2017 . 29077387 . 10.1021/acschemneuro.7b00319 .
  3. Wu H, Wu C, Zhou Y, Huang S, Zhu S . Catatonia in adult anti-NMDAR encephalitis: an observational cohort study . BMC Psychiatry . 23 . 1 . 94 . February 2023 . 36750806 . 9903498 . 10.1186/s12888-022-04505-x . free .
  4. Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F . An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models . The Lancet. Neurology . 18 . 11 . 1045–1057 . November 2019 . 31326280 . 10.1016/S1474-4422(19)30244-3 . 197464804 .
  5. Kayser MS, Dalmau J . Anti-NMDA receptor encephalitis, autoimmunity, and psychosis . Schizophrenia Research . 176 . 1 . 36–40 . September 2016 . 25458857 . 4409922 . 10.1016/j.schres.2014.10.007 .
  6. Kayser MS, Dalmau J . Anti-NMDA Receptor Encephalitis in Psychiatry . Current Psychiatry Reviews . 7 . 3 . 189–193 . 2011 . 24729779 . 3983958 . 10.2174/157340011797183184 .
  7. Book: https://www.ncbi.nlm.nih.gov/books/NBK551672/. StatPearls. Anti-NMDA Receptor Encephalitis. 2022. StatPearls. 31869136. Samanta D, Lui F. 2021-11-20. 2021-12-06. https://web.archive.org/web/20211206231943/https://www.ncbi.nlm.nih.gov/books/NBK551672/. live.
  8. Book: Minagar A, Alexander JS . Inflammatory Disorders of the Nervous System: Pathogenesis, Immunology, and Clinical Management . 2017 . Humana Press . 978-3-319-51220-4 . 177 . 14 July 2018 . en . 1 July 2024 . https://web.archive.org/web/20240701230152/https://books.google.com/books?id=FoZtDgAAQBAJ&pg=PA177#v=onepage&q&f=false . live .
  9. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR . Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma . Annals of Neurology . 61 . 1 . 25–36 . January 2007 . 17262855 . 2430743 . 10.1002/ana.21050 .
  10. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR . Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies . The Lancet. Neurology . 7 . 12 . 1091–1098 . December 2008 . 18851928 . 2607118 . 10.1016/S1474-4422(08)70224-2 .
  11. Wang . Hai-Yang . Yang . Xiao-Yu . Han . Jinming . Liu . Huakun . Yan . Zhong-Rui . Liang . Zhanhua . 2022-03-10 . Clinical characteristics of anti-N-methyl-d-aspartate receptor encephalitis in patients with a long-term history of mental disorders . European Journal of Medical Research . 27 . 1 . 38 . 10.1186/s40001-022-00664-5 . free . 2047-783X . 8908639 . 35272706.
  12. Book: Agarwal R, Gupta V . Anti-NMDA Receptor Encephalitis In Children . 2022 . StatPearls . Treasure Island (FL) . StatPearls Publishing . 32965889 . 2023-02-24 . 2024-07-01 . https://web.archive.org/web/20240701230154/https://www.ncbi.nlm.nih.gov/books/NBK562218/ . live .
  13. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R . Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis . The Lancet. Neurology . 10 . 1 . 63–74 . January 2011 . 21163445 . 3158385 . 10.1016/s1474-4422(10)70253-2 .
  14. Greiner H, Leach JL, Lee KH, Krueger DA . Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome . Seizure . 20 . 3 . 266–270 . April 2011 . 21146427 . 10.1016/j.seizure.2010.11.013 . 5839321 . free .
  15. Book: Cahalan S . Brain on Fire-My Month of Madness . New York . Simon & Schuster . 2013 .
  16. Eyre M, Kaushik A, Barrett E, King MD, Pollak T, Dale RC, Byrne S, Lim M . 2020 . Catatonic features in children and adolescents with N-methyl-d-aspartate receptor antibody encephalitis . BJPsych Open . en . 6 . 4 . e71 . 10.1192/bjo.2020.55 . 38424748 . 2056-4724 . 7443916.
  17. Li Y, Yang K, Zhang F, Wang J, Shen H, Liu M, Guo J, Wang J . Identification of cerebrospinal fluid biomarker candidates for anti-N-methyl-D-aspartate receptor encephalitis: High-throughput proteomic investigation . Frontiers in Immunology . 13 . 971659 . 2022 . 36389787 . 9643472 . 10.3389/fimmu.2022.971659 . free .
  18. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A . N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes . Brain . 133 . Pt 6 . 1655–1667 . June 2010 . 20511282 . 2877907 . 10.1093/brain/awq113 .
  19. Suh-Lailam BB, Haven TR, Copple SS, Knapp D, Jaskowski TD, Tebo AE . Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay . Clinica Chimica Acta; International Journal of Clinical Chemistry . 421 . 1–6 . June 2013 . 23454475 . 10.1016/j.cca.2013.02.010 .
  20. Moscato EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice-Gordon RJ . Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies . The European Journal of Neuroscience . 32 . 2 . 298–309 . July 2010 . 20646055 . 2955837 . 10.1111/j.1460-9568.2010.07349.x .
  21. Rabchevsky AG, Degos JD, Dreyfus PA . Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis . Brain Research . 832 . 1–2 . 84–96 . June 1999 . 10375654 . 10.1016/S0006-8993(99)01479-1 . 27036707 .
  22. Malviya M, Barman S, Golombeck KS, Planagumà J, Mannara F, Strutz-Seebohm N, Wrzos C, Demir F, Baksmeier C, Steckel J, Falk KK, Gross CC, Kovac S, Bönte K, Johnen A, Wandinger KP, Martín-García E, Becker AJ, Elger CE, Klöcker N, Wiendl H, Meuth SG, Hartung HP, Seebohm G, Leypoldt F, Maldonado R, Stadelmann C, Dalmau J, Melzer N, Goebels N . NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody . Annals of Clinical and Translational Neurology . 4 . 11 . 768–783 . November 2017 . 29159189 . 5682115 . 10.1002/acn3.444 .
  23. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J . Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents . Annals of Neurology . 66 . 1 . 11–18 . July 2009 . 19670433 . 2826225 . 10.1002/ana.21756 .
  24. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, Dalmau J, Balice-Gordon RJ . Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis . The Journal of Neuroscience . 30 . 17 . 5866–5875 . April 2010 . 20427647 . 2868315 . 10.1523/JNEUROSCI.0167-10.2010 .
  25. Book: Abbas AK, Lichtman AH, Pillai S . Cellular and Molecular Immunology . 2011 . Elsevier Health Sciences . 7th . 978-1-4377-3573-4.
  26. Bacchi S, Franke K, Wewegama D, Needham E, Patel S, Menon D . Magnetic resonance imaging and positron emission tomography in anti-NMDA receptor encephalitis: A systematic review . Journal of Clinical Neuroscience . 52 . 54–59 . June 2018 . 29605275 . 10.1016/j.jocn.2018.03.026 . 4565748 . 2023-02-24 . 2021-06-14 . https://web.archive.org/web/20210614162633/https://www.repository.cam.ac.uk/handle/1810/276054 . live .
  27. Gillinder L, Warren N, Hartel G, Dionisio S, O'Gorman C . EEG findings in NMDA encephalitis - A systematic review . Seizure . 65 . 20–24 . February 2019 . 30597400 . 10.1016/j.seizure.2018.12.015 . free .
  28. Blinder T, Lewerenz J . Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis . Frontiers in Neurology . 10 . 804 . 2019-07-25 . 31404257 . 6670288 . 10.3389/fneur.2019.00804 . free .
  29. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J . A clinical approach to diagnosis of autoimmune encephalitis . The Lancet. Neurology . 15 . 4 . 391–404 . April 2016 . 26906964 . 5066574 . 10.1016/s1474-4422(15)00401-9 .
  30. Liba Z, Sebronova V, Komarek V, Sediva A, Sedlacek P . Prevalence and treatment of anti-NMDA receptor encephalitis . The Lancet. Neurology . 12 . 5 . 424–425 . May 2013 . 23602156 . 10.1016/S1474-4422(13)70070-X . 31746114 . free .
  31. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA . The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project . Clinical Infectious Diseases . 54 . 7 . 899–904 . April 2012 . 22281844 . 3297648 . 10.1093/cid/cir1038 .
  32. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J . Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study . The Lancet. Neurology . 12 . 2 . 157–165 . February 2013 . 23290630 . 3563251 . 10.1016/S1474-4422(12)70310-1 .
  33. Web site: Lamas DJ . When the brain is under attack . . 27 May 2013 . 4 July 2017 . 26 March 2018 . https://web.archive.org/web/20180326191725/http://www.bostonglobe.com/lifestyle/health-wellness/2013/05/26/when-brain-attacks-newly-discovered-disease-can-mimic-psychosis/dyixxnwdHJJIUITsNYJC3O/story.html . live .
  34. Tam J, Zandi MS . The witchcraft of encephalitis in Salem . Journal of Neurology . 264 . 7 . 1529–1531 . July 2017 . 28631128 . 10.1007/s00415-017-8546-4 . 36151332 .
  35. Sébire G . In search of lost time from "Demonic Possession" to anti-N-methyl-D-aspartate receptor encephalitis . Annals of Neurology . 67 . 1 . 141–142 . January 2010 . 20186949 . 10.1002/ana.21928 . 2366741 .
  36. Web site: A YoungReporter Chronicles Her 'Brain On Fire' . Fresh Air . WHYY; NPR . November 14, 2012 . September 20, 2013 . June 18, 2018 . https://web.archive.org/web/20180618052628/https://www.npr.org/2012/11/14/165115921/a-young-reporter-chronicles-her-brain-on-fire . live .
  37. News: Hornaday A, O'Sullivan M . What to watch with your kids: 'Ant-Man and the Wasp,' 'Leave No Trace' and more . 14 July 2018 . Washington Post . en . 27 August 2021 . https://web.archive.org/web/20210827221807/https://www.washingtonpost.com/goingoutguide/movies/what-to-watch-with-your-kids-ant-man-and-the-wasp-leave-no-trace-and-more/2018/07/05/2734a31c-7a4e-11e8-80be-6d32e182a3bc_story.html?noredirect=on . live .
  38. Web site: Whitmire K. Cowboys' Okoye returns to practice after battling rare brain disease. www.foxsports.com. FOX Sports Southwest. 24 October 2014. 2014-10-23. 2019-04-22. https://web.archive.org/web/20190422015059/https://www.foxsports.com/southwest/story/cowboys-okoye-returns-to-practice-after-battling-rare-brain-disease-102314. live.
  39. Web site: Nuwer R. Rachel Nuwer. Knut the Polar Bear's Mysterious Death Finally Solved. Smithsonian. 27 August 2015. 27 August 2015. 6 October 2018. https://web.archive.org/web/20181006195426/https://www.smithsonianmag.com/science-nature/knut-polar-bears-mysterious-death-finally-solved-180956414/. live.
  40. Armitage H . Death of beloved polar bear, Knut, solved . Science . 27 August 2015 . 10.1126/science.aad1675 . 30 June 2022 . 14 October 2023 . https://web.archive.org/web/20231014121727/https://www.science.org/content/article/death-beloved-polar-bear-knut-solved . live .
  41. Prüss H, Leubner J, Wenke NK, Czirják GÁ, Szentiks CA, Greenwood AD . Anti-NMDA Receptor Encephalitis in the Polar Bear (Ursus maritimus) Knut . Scientific Reports . 5 . 12805 . 12805 . August 2015 . 26313569 . 4551079 . 10.1038/srep12805 . 2015NatSR...512805P .
  42. Web site: Pitt A . Encephalitis Society . North Yorkshire . Hannibal and Anti-NMDAR Encephalitis . 21 February 2018 . 28 February 2021 . 16 February 2021 . https://web.archive.org/web/20210216181528/https://www.encephalitis.info/Blog/hannibal-and-anti-nmdar-encephalitis . live .
  43. Web site: Kaplan . Michael . How a Post reporter changed the course of medical history . New York Post . 2017-08-27 . 2024-07-22.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Anti-NMDA receptor encephalitis".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.